Physician profile
Sanjay Gupta
NPI 1134116601
$2,778.46
in general payments reported to CMS, 2019-2025
29 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $426 · 2021: $215 · 2022: $265 · 2023: $372 · 2024: $775 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045 · Travel and Lodging: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.42 |
| Travel and Lodging | $407.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $661.68 | 2023-2024 | Pulseselect, Endurant Iis, Abre |
| Inari Medical, INC. | $352.84 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amgen INC. | $254.09 | 2019-2025 | Repatha |
| Novo Nordisk INC | $226.29 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $197.31 | 2019-2024 | |
| Stryker Corporation | $170.05 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Medtronic Vascular, INC. | $126.20 | 2019 | |
| Amarin Pharma, INC. | $101.04 | 2019-2021 | |
| Abbott Laboratories | $98.16 | 2022-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $65.14 | 2020-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $64.56 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $55.84 | 2020-2023 | Eliquis |
| Merck Sharp & Dohme LLC | $42.72 | 2021 | |
| Sanofi-Aventis U.S. LLC | $39.36 | 2024-2025 | |
| Tactile Systems Technology INC | $37.42 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $37.34 | 2019-2020 | |
| Lilly USA, LLC | $35.14 | 2019-2020 | |
| Allergan, INC. | $34.97 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.67 | 2025 | |
| Phathom Pharmaceuticals, INC. | $19.90 | 2024 | Voquezna |
| Exact Sciences Corporation | $19.51 | 2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.33 | 2020 | |
| Esperion Therapeutics, INC. | $16.74 | 2020 | |
| Shield Therapeutics INC | $14.43 | 2023 | Accrufer |
| Xeris Pharmaceuticals, INC. | $13.73 | 2025 | Gvoke Hypopen |
| Melinta Therapeutics, LLC | $13.49 | 2019 | |
| Mylan Specialty L.P. | $13.37 | 2020 | |
| Avanir Pharmaceuticals, INC. | $12.66 | 2019 | |
| Eisai INC. | $12.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.